Apogee Therapeutics: AbbVie's $10.9 Billion Bet on Next-Gen ImmunologyAbbVie's $10.9 billion acquisition of Apogee Therapeutics with a 49.49% premium highlights the value of next-generation immunology and the promise of zumilokibart.Jun 224 min